Paul I Terasaki
Overview
Explore the profile of Paul I Terasaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cail J, Huang W, Terasaki P, Everly M, Briley K, Haisch C, et al.
Clin Transpl
. 2014 Aug;
:319-24.
PMID: 25095524
Donor specific human leukocyte antigen (HLA) antibodies (DSA) are a significant cause of allograft failure. However, it has been reported that some DSA negative patients still experience allograft failure. In...
12.
Ravindranath M, Zhu D, Pham T, Jucaud V, Hopfield J, Kawakita S, et al.
Clin Transpl
. 2014 Aug;
:293-305.
PMID: 25095521
Healthy individuals have natural antibodies (Abs) reacting to allo-human leukocyte antigen (HLA)-la. This could be due to the presence of anti-HLA-E immunoglobulin G (IgG), which was revealed to recognize the...
13.
OLeary J, Shiller S, Bellamy C, Nalesnik M, Kaneku H, Jennings L, et al.
Liver Transpl
. 2014 Jul;
20(10):1244-55.
PMID: 25045154
Acute antibody-mediated rejection (AMR) occurs in a small minority of sensitized liver transplant recipients. Although histopathological characteristics have been described, specific features that could be used (1) to make a...
14.
Ohe H, Uchida Y, Yoshizawa A, Hirao H, Taniguchi M, Maruya E, et al.
Transplantation
. 2014 Jun;
98(10):1105-11.
PMID: 24914568
Background: Many pediatric patients who receive a living-donor liver transplant undergo withdrawal of immunosuppression (IS). For them, the high incidence of long-term progressive graft fibrosis is of particular concern. Methods:...
15.
Dieplinger G, Everly M, Rebellato L, Haisch C, Briley K, Bolin P, et al.
Transplantation
. 2014 Jun;
98(10):1097-104.
PMID: 24911039
Background: Many patients develop de novo donor-specific anti-human leukocyte antigen antibodies (dnDSA) after transplantation. Despite development of dnDSA, not all patients will immediately fail. This study analyzes dnDSA intensity and...
16.
OLeary J, Kaneku H, Jennings L, Susskind B, Terasaki P, Klintmalm G
Liver Transpl
. 2014 Mar;
20(6):655-63.
PMID: 24678017
Hepatitis C virus (HCV) fibrosis progression after liver transplantation (LT) is accelerated in comparison with fibrosis progression before transplantation. The vast majority of the risk factors for fibrosis progression after...
17.
Everly M, Rebellato L, Haisch C, Briley K, Bolin P, Kendrick W, et al.
Transplantation
. 2014 Feb;
97(5):494-501.
PMID: 24487396
Background: With standard IgG donor-specific anti-HLA antibody (DSA) testing, it is unclear which immunoglobulin-G (IgG) DSA positive patients will fail. We looked further into the immune response by studying immunoglobulin-M...
18.
OLeary J, Kaneku H, Demetris A, Marr J, Shiller S, Susskind B, et al.
Liver Transpl
. 2014 Jan;
20(2):218-27.
PMID: 24382837
We analyzed 60 patients with idiopathic early allograft loss (defined as death or retransplantation at <90 days) to determine the relative contribution of preformed donor-specific human leukocyte antigen alloantibodies (DSAs)...
19.
Sasaki T, Ravindranath M, Terasaki P, Freitas M, Kawakita S, Jucaud V
Int J Cancer
. 2013 Oct;
134(7):1558-70.
PMID: 24105714
Phenotypic expression of human leukocyte antigen (HLA)-E on the surface of tumor lesions includes intact heterodimer [HLA-E heavy chain and β2-microglobulin (β2m)] and β2m-free monomer. Anti-HLA-E monoclonal antibodies (mAbs), MEM-E/02...
20.
Wu P, Everly M, Rebellato L, Haisch C, Briley K, Bolin P, et al.
Transplantation
. 2013 Aug;
96(10):919-25.
PMID: 23912173
Background: Approximately 7% to 9% of patients with donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) fail within 1 year post-DSA onset. However, little is known as to how this DSA-associated...